SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
124 hedge funds and large institutions have $196M invested in SANGAMO THERAPEUTICS INC in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 25 closing their positions.
261% more call options, than puts
Call options by funds: $5.37M | Put options by funds: $1.49M
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
9% less funds holding
Funds holding: 136 → 124 (-12)
27% less capital invested
Capital invested by funds: $268M → $196M (-$71.4M)
48% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 25
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$4.23M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$2.74M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.64M |
| 4 |
Renaissance Technologies
New York
|
+$2.44M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$15.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.74M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$2.4M |
| 4 |
SCM
Suffolk Capital Management
New York
|
-$1.43M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.36M |
SGMO Hedge Fund Activity: Q3 2016 in Review
124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2016, worth a combined $196M — down 27% from $268M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SGMO and 13 opened new positions — a net loss of 12 holders — while 30 trimmed existing stakes and 44 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $4.23M. The largest seller was Bank of New York Mellon, cutting an estimated $15.4M.
- 124 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2016, down from 136 in Q2 2016.
- Funds reported $196M of SANGAMO THERAPEUTICS INC stock for Q3 2016, down 27% quarter-over-quarter.
- 13 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2016 and 25 closed out, a net change of -12 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2016 was OrbiMed, an estimated $4.23M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2016 was Bank of New York Mellon, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2016.